Gyre Therapeutics
GYRE
58 hedge funds and large institutions have $73.1M invested in Gyre Therapeutics in 2026 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 8 closing their positions.
938% more capital inflows, than outflows
Capital inflows: $9.6M | Capital outflows: $922K
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
1.16% more ownership
Funds ownership: 7.78% → 8.95% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 59 → 58 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$3.93M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.23M |
| 3 |
BlackRock
New York
|
+$1.21M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$988K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$615K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$175K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$170K |
| 3 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$112K |
| 4 |
Morgan Stanley
New York
|
-$82.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$80.4K |
GYRE Hedge Fund Activity: Q3 2026 in Review
58 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2026, worth a combined $73.1M — up 28% from $57.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GYRE and 7 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 23 added.
The largest buyer was Vanguard Capital Management, adding an estimated $3.93M. The largest seller was Goldman Sachs, cutting an estimated $175K.
- 58 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2026, down from 59 in Q2 2026.
- Funds reported $73.1M of Gyre Therapeutics stock for Q3 2026, up 28% quarter-over-quarter.
- 7 funds opened new Gyre Therapeutics positions in Q3 2026 and 8 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q3 2026 was Vanguard Capital Management, an estimated $3.93M added.
- The largest Gyre Therapeutics seller in Q3 2026 was Goldman Sachs, an estimated $175K sold.
Based on aggregated 13F filings for Q3 2026.